


=> d 11
 L1 HAS NO ANSWERS
 L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11
 SAMPLE SEARCH INITIATED 16:15:40 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 5882 TO ITERATE
 34.0% PROCESSED 2000 ITERATIONS 2 ANSWERS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01
 FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 113041 TO 122239
 PROJECTED ANSWERS: 2 TO 262

L2 2 SEA SSS SAM L1

=> s 11 ful
 FULL SEARCH INITIATED 16:15:46 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 118814 TO ITERATE

100.0% PROCESSED 118814 ITERATIONS
 SEARCH TIME: 00.00.01

78 ANSWERS

L3 78 SEA SSS FUL L1

=> file caplus
 COST IN U.S. DOLLARS SINCE FILE TOTAL
 FULL ESTIMATED COST ENTRY SESSION
 185.88 186.10

FILE 'CAPLUS' ENTERED AT 16:15:51 ON 21 AUG 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Aug 2009 VOL 151 ISS 9
 FILE LAST UPDATED: 20 Aug 2009 (20090820/ED)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>


This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

=> s 13
 L4 3 L3

=> d abs fbib hitstr 1-3

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN
 GI



AB Title compds. I [wherein R1, R2 = OH or (cyclo)alkoxy; R3, R31 = H or alkyl; R4 = OH, alkoxy or alkylcarbonyloxy; R5 = H or alkyl; R6 = H, halo, alkyl or alkoxy; R7 = (un)substituted NH₂; etc., or their salts and the N-oxides, and the salts of the N-oxides] were prepared as PDE4 inhibitors. For instance, II (R = OH) was synthesized by hydrolysis of its ester II (R = OAc) with Cs₂CO₃ in methanol. Representative I, including II (R = OH), were found to inhibit PDE4B2 with pIC₅₀ values of 6.42 – 9.02. Therefore, I and pharmaceutical compns. thereof are useful for treating PDE-mediated disorders, such as respiratory diseases.

AN 2005:1026938 CAPLUS

DN 143:326233

TI Preparation of amido-substituted phenylphenanthridines as PDE4 inhibitors for the treatment of respiratory diseases

IN Schmidt, Beate; Kautz, Ulrich

PA Altana Pharma AG, Germany; Kautz, Ulrich

SO PCT Int. Appl., 107 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.

PI	WO 2005087745	A1	20050922	WO 2005-EP51054	20050309
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

EP 2004-100990


A 20040310

AU 2005221832	A1	20050922	EP 2004-106677	A	20041217
			AU 2005-221832		20050309
			EP 2004-100990	A	20040310
			EP 2004-106677	A	20041217
			WO 2005-EP51054	W	20050309
CA 2558391	A1	20050922	CA 2005-2558391		20050309
			EP 2004-100990	A	20040310
			EP 2004-106677	A	20041217
			WO 2005-EP51054	W	20050309
EP 1725534	A1	20061129	EP 2005-740073		20050309
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			EP 2004-100990	A	20040310
			EP 2004-106677	A	20041217
			WO 2005-EP51054	W	20050309
CN 1926113	A	20070307	CN 2005-80006855		20050309
			EP 2004-100990	A	20040310
			EP 2004-106677	A	20041217
			WO 2005-EP51054	W	20050309
BR 2005008481	A	20070731	BR 2005-8481		20050309
			EP 2004-100990	A	20040310
			EP 2004-106677	A	20041217
			WO 2005-EP51054	W	20050309
JP 2007527901	T	20071004	JP 2007-502343		20050309
			EP 2004-100990	A	20040310
			EP 2004-106677	A	20041217
			WO 2005-EP51054	W	20050309
ZA 2006006669	A	20080227	ZA 2006-6669		20060811
			EP 2004-100990	A	20040310
MX 2006009892	A	20070301	MX 2006-9892		20060831
			EP 2004-100990	A	20040310
			EP 2004-106677	A	20041217
			WO 2005-EP51054	W	20050309
US 20070185149	A1	20070809	US 2006-591480		20060927
			EP 2004-100990	A	20040310
			EP 2004-106677	A	20041217
			WO 2005-EP51054	W	20050309
NO 2006004415	A	20061010	NO 2006-4415		20060929
			EP 2004-100990	A	20040310
			EP 2004-106677	A	20041217
			WO 2005-EP51054	W	20050309
KR 2006130697	A	20061219	KR 2006-720318		20060929
			EP 2004-100990	A	20040310
			EP 2004-106677	A	20041217
			WO 2005-EP51054	W	20050309
IN 2006MN01169	A	20070413	IN 2006-MN1169		20061003
			EP 2004-100990	A	20040310
			WO 2005-EP51054	W	20050309
OS	CASREACT 143:326233; MARPAT 143:326233				
IT	865306-88-3P				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (inhibitor; preparation of amido-substituted phenylphenanthridines as PDE4 inhibitors for the treatment of respiratory diseases)				

RN 865306-88-3 CAPLUS



CN Benzoic acid, 4-[(2R,4aR,10bR)-2-(acetyloxy)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-, 2-[3-(aminosulfonyl)phenyl]hydrazide, rel-(CA INDEX NAME)

Relative stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN
 GI




AB Title compds. I [wherein R1, R2 = OH or (cyclo)alkoxy; R3, R31 = H or alkyl; R4 = OH, alkoxy or alkylcarbonyloxy; R5 = H or alkyl; R6 = H, halo, alkyl or alkoxy; R7 = (un)substituted SO2NH2; etc., or their salts and the N-oxides, and the salts of the N-oxides] were prepared as PDE4 inhibitors.

For instance, II (R = OH) was synthesized by hydrolysis of its ester II (R = OAc) with Cs₂CO₃ in methanol. Representative I, including II (R = OH), were found to inhibit PDE4B2 with pIC₅₀ values of 7.52 – 10.06. Therefore, I and pharmaceutical compns. thereof are useful for treating PDE-mediated disorders, such as respiratory diseases.


AN 2005:1026937 CAPLUS
 DN 143:347065
 TI Preparation of thio-containing phenylphenanthridines as PDE4 inhibitors for the treatment of respiratory diseases
 IN Schmidt, Beate; Flockerzi, Dieter; Hatzelmann, Armin; Zitt, Christof; Barsig, Johannes; Marx, Degenhard; Kley, Hans-Peter; Kautz, Ulrich
 PA Altana Pharma A.-G., Germany
 SO PCT Int. Appl., 76 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005087744	A1	20050922	WO 2005-EP51052	20050309
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				EP 2004-100988	A 20040310
				EP 2005-100692	A 20050201
AU	2005221831	A1	20050922	AU 2005-221831	20050309
				EP 2004-100988	A 20040310
				EP 2005-100692	A 20050201
				WO 2005-EP51052	W 20050309
CA	2558390	A1	20050922	CA 2005-2558390	20050309
				EP 2004-100988	A 20040310
				EP 2005-100692	A 20050201
				WO 2005-EP51052	W 20050309
EP	1725533	A1	20061129	EP 2005-716969	20050309
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			EP 2004-100988	A 20040310
				EP 2005-100692	A 20050201
				WO 2005-EP51052	W 20050309
CN	1938275	A	20070328	CN 2005-80006802	20050309
				EP 2004-100988	A 20040310
				EP 2005-100692	A 20050201
				WO 2005-EP51052	W 20050309
BR	2005008473	A	20070731	BR 2005-8473	20050309
				EP 2004-100988	A 20040310
				EP 2005-100692	A 20050201
				WO 2005-EP51052	W 20050309


JP 2007527900	T	20071004	JP 2007-502342	20050309
			EP 2004-100988	A 20040310
			EP 2005-100692	A 20050201
			WO 2005-EP51052	W 20050309
ZA 2006006671	A	20080227	ZA 2006-6671	20060811
			EP 2004-100988	A 20040310
MX 2006010045	A	20061115	MX 2006-10045	20060904
			EP 2004-100988	A 20040310
			EP 2005-100692	A 20050201
			WO 2005-EP51052	W 20050309
US 20080161339	A1	20080703	US 2006-591768	20060927
			EP 2004-100988	A 20040310
			EP 2005-100692	A 20050201
			WO 2005-EP51052	W 20050309
NO 2006004416	A	20061207	NO 2006-4416	20060929
			EP 2004-100988	A 20040310
			EP 2005-100692	A 20050201
			WO 2005-EP51052	W 20050309
KR 2006124783	A	20061205	KR 2006-720591	20061002
			EP 2004-100988	A 20040310
			EP 2005-100692	A 20050201
			WO 2005-EP51052	W 20050309
IN 2006MN01170	A	20070518	IN 2006-MN1170	20061003
			EP 2004-100988	A 20040310
			WO 2005-EP51052	W 20050309
OS CASREACT 143:347065; MARPAT 143:347065				
IT 1044702-80-8 1044702-83-1 1044702-84-2				
1044702-85-3 1044702-88-6 1044702-91-1				
1044702-92-2 1044702-93-3 1044702-96-6				
1044702-99-9				
RL: PRPH (Prophetic)				
(Preparation of thio-containing phenylphenanthridines as PDE4 inhibitors for the treatment of respiratory diseases)				
RN 1044702-80-8 CAPLUS				
CN 2-Phenanthridinol, 9-(2,2-difluoroethoxy)-1,2,3,4,4a,10b-hexahydro-8- methoxy-6-[4-(1-pyrrolidinylsulfonyl)phenyl]-, 2-acetate (CA INDEX NAME)				




RN 1044702-83-1 CAPLUS
 CN Methanesulfonamide, N-[4-[8-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-2-
hydroxy-9-methoxy-6-phenanthridinyl]phenyl]- (CA INDEX NAME)




RN 1044702-84-2 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED



RN 1044702-85-3 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1044702-88-6 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED



RN 1044702-91-1 CAPLUS

CN 2-Phenanthridinol, 9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-[3-(methylsulfinyl)phenyl]-, (2R,4aR,10bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 1044702-92-2 CAPLUS


CN 2-Phenanthridinol, 9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-[3-(methylthio)phenyl]-, (2R,4aR,10bR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044702-93-3 CAPLUS


CN 2-Phenanthridinol, 9-(2,2-difluoroethoxy)-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-[4-(methylthio)phenyl]-, 2-acetate (CA INDEX NAME)



RN 1044702-96-6 CAPLUS


CN 2-Phenanthridinol, 9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-[4-(methylsulfinyl)phenyl]-, (2R,4aR,10bR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1044702-99-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



IT 865291-76-5P 865291-77-6P 865291-78-7P

865291-79-8P 865291-81-2P 865291-82-3P

865291-83-4P 865291-84-5P 865291-85-6P

865291-86-7P 865291-87-8P 865292-08-6P

865292-09-7P 865292-10-0P 865292-11-1P

865292-13-3P 865292-14-4P 865292-15-5P

865292-16-6P 865292-17-7P 865292-18-8P

865292-19-9P 865292-20-2P 865292-21-3P

865292-22-4P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (inhibitor; preparation of thio-containing phenylphenanthridines as PDE4 inhibitors for treatment of respiratory diseases)

RN 865291-76-5 CAPLUS

CN Benzenesulfonamide, N-[4-[(2R,4aR,10bR)-2-(acetoxy)-1,2,3,4,4a,10b-

hexahydro-8,9-dimethoxy-6-phenanthridinylphenyl]-4-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-77-6 CAPLUS

CN Benzenesulfonamide, N-[4-[(2R,4aR,10bR)-2-(acetyloxy)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]phenyl]-N,4-dimethyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-78-7 CAPLUS

CN Benzenesulfonamide, N-[4-[(2R,4aR,10bR)-2-(acetyloxy)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]phenyl]-4-fluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-79-8 CAPLUS

CN Benzenesulfonamide, N-[4-[(2R,4aR,10bR)-2-(acetoxy)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-2-methylphenyl]-4-methyl-, rel-(CA INDEX NAME)


Relative stereochemistry.



RN 865291-81-2 CAPLUS

CN Benzenesulfonamide, N-[4-[(2R,4aR,10bR)-2-(acetoxy)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]phenyl]methyl]-4-methyl-, rel-(CA INDEX NAME)


Relative stereochemistry.



RN 865291-82-3 CAPLUS

CN Methanesulfonamide, N-[4-[(2R, 4aR, 10bR)-2-(acetyloxy)-8-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-9-methoxy-6-phenanthridinyl]phenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-83-4 CAPLUS

CN Benzenesulfonamide, N-[4-[(2R, 4aR, 10bR)-2-(acetyloxy)-8-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-9-methoxy-6-phenanthridinyl]phenyl]-4-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-84-5 CAPLUS

CN Benzenesulfonamide, N-[4-[(2R,4aR,10bR)-2-(acetyloxy)-8-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-9-methoxy-6-phenanthridinyl]phenyl]-4-fluoro-,
rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-85-6 CAPLUS

CN Benzenesulfonamide, N-[[(2R,4aR,10bR)-2-(acetyloxy)-8-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-9-methoxy-6-phenanthridinyl]phenyl]methyl]-4-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-86-7 CAPLUS

CN Benzenesulfonamide, N-[4-[(2R,4aR,10bR)-2-(acetoxy)-9-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-phenanthridinyl]phenyl]-4-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-87-8 CAPLUS

CN Benzenesulfonamide, N-[4-[(2R,4aR,10bR)-2-(acetoxy)-9-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-phenanthridinyl]phenyl]methyl]-4-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865292-08-6 CAPLUS

CN Benzenesulfonamide, 4-[(2R,4aR,10bR)-2-(acetyloxy)-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-phenanthridinyl]-N,N-dipropyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865292-09-7 CAPLUS

CN Benzenesulfonamide, 4-[(2R,4aR,10bR)-2-(acetyloxy)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-phenanthridinyl]-N,N-dipropyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865292-10-0 CAPLUS

CN Benzenesulfonamide, 4-[(2R,4aR,10bR)-2-(acetyloxy)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-phenanthridinyl]-N-(2-methoxyethyl)-N-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865292-11-1 CAPLUS

CN 2-Phenanthridinol, 8-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-9-methoxy-6-[4-(1-pyrrolidinylsulfonyl)phenyl]-, 2-acetate, (2R,4aR,10bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865292-13-3 CAPLUS

CN 2-Phenanthridinol, 8-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-9-methoxy-6-[3-(1-pyrrolidinylsulfonyl)phenyl]-, 2-acetate, (2R,4aR,10bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865292-14-4 CAPLUS

CN Benzenesulfonamide, 4-[(2R,4aR,10bR)-2-(acetoxymethyl)-8-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-9-methoxy-6-phenanthridinyl]-N,N-dipropyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865292-15-5 CAPLUS

CN 2-Phenanthridinol, 8-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-9-methoxy-6-[3-(4-morpholinylsulfonyl)phenyl]-, 2-acetate, (2R,4aR,10bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865292-16-6 CAPLUS

CN Benzenesulfonamide, 3-[(2R,4aR,10bR)-2-(acetyloxy)-8-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-9-methoxy-6-phenanthridinyl]-N,N-dimethyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865292-17-7 CAPLUS

CN Benzenesulfonamide, 3-[(2R,4aR,10bR)-2-(acetyloxy)-8-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-9-methoxy-6-phenanthridinyl]-N-cyclopropyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865292-18-8 CAPLUS

CN Benzenesulfonamide, 3-[(2R,4aR,10bR)-2-(acetyloxy)-8-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-9-methoxy-6-phenanthridinyl]-N,N-bis(2-methoxyethyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865292-19-9 CAPLUS

CN 2-Phenanthridinol, 8-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-9-methoxy-6-[3-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, 2-acetate, (2R,4aR,10bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865292-20-2 CAPLUS

CN 2-Phenanthridinol, 1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-[3-(methylsulfonyl)phenyl]-, 2-acetate, (2R,4aR,10bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865292-21-3 CAPLUS

CN 2-Phenanthridinol, 9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-[4-(methylthio)phenyl]-, 2-acetate, (2R,4aR,10bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865292-22-4 CAPLUS

CN 2-Phenanthridinol, 9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-[4-(methylthio)phenyl]-, 2-acetate, (2R,4aR,10bR)- (CA INDEX NAME)

Absolute stereochemistry.



IT 865291-65-2P 865291-66-3P 865291-67-4P

865291-68-5P 865291-69-6P 865291-70-9P

865291-71-0P 865291-72-1P 865291-73-2P

865291-74-3P 865291-75-4P 865291-88-9P

865291-89-0P 865291-90-3P 865291-91-4P

865291-92-5P 865291-93-6P 865291-94-7P

865291-95-8P 865291-96-9P 865291-97-0P

865291-98-1P 865291-99-2P 865292-00-8P

865292-01-9P 865292-02-0P 865292-03-1P

865292-04-2P 865292-05-3P 865292-06-4P

865292-07-5P 865292-23-5P 865292-34-8P

865292-35-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES


(Uses)

(inhibitor; preparation of thio-containing phenylphenanthridines as PDE4 inhibitors for treatment of respiratory diseases)

RN 865291-65-2 CAPLUS

CN Benzenesulfonamide, N-[4-[(2R, 4aR, 10bR)-1, 2, 3, 4, 4a, 10b-hexahydro-2-hydroxy-8, 9-dimethoxy-6-phenanthridinyl]phenyl]-N, 4-dimethyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-66-3 CAPLUS

CN Benzenesulfonamide, 4-fluoro-N-[4-[(2R, 4aR, 10bR)-1, 2, 3, 4, 4a, 10b-hexahydro-2-hydroxy-8, 9-dimethoxy-6-phenanthridinyl]phenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-67-4 CAPLUS

CN Benzenesulfonamide, N-[4-[(2R, 4aR, 10bR)-1, 2, 3, 4, 4a, 10b-hexahydro-2-hydroxy-8, 9-dimethoxy-6-phenanthridinyl]-2-methylphenyl]-4-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-68-5 CAPLUS

CN Benzenesulfonamide, N-[4-[(2R, 4aR, 10bR)-1, 2, 3, 4, 4a, 10b-hexahydro-2-hydroxy-8, 9-dimethoxy-6-phenanthridinyl]phenyl]methyl]-4-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-69-6 CAPLUS

CN Methanesulfonamide, N-[4-[(2R, 4aR, 10bR)-8-(difluoromethoxy)-1, 2, 3, 4, 4a, 10b-hexahydro-2-hydroxy-9-methoxy-6-phenanthridinyl]phenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-70-9 CAPLUS

CN Benzenesulfonamide, N-[4-[(2R,4aR,10bR)-8-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-9-methoxy-6-phenanthridinyl]phenyl]-4-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-71-0 CAPLUS

CN Benzenesulfonamide, N-[4-[(2R,4aR,10bR)-8-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-9-methoxy-6-phenanthridinyl]phenyl]-4-fluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-72-1 CAPLUS

CN Benzenesulfonamide, N-[4-[(2R, 4aR, 10bR)-8-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-9-methoxy-6-phenanthridinyl]phenyl]methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-73-2 CAPLUS

CN Benzenesulfonamide, N-[4-[(2R, 4aR, 10bR)-9-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8-methoxy-6-phenanthridinyl]phenyl]-4-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-74-3 CAPLUS

CN Benzenesulfonamide, N-[4-[(2R,4aR,10bR)-9-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8-methoxy-6-phenanthridinyl]phenyl]methyl]-4-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-75-4 CAPLUS

CN Benzenesulfonamide, N-[4-[(2R,4aR,10bR)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8,9-dimethoxy-6-phenanthridinyl]phenyl]-4-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-88-9 CAPLUS

CN Benzenesulfonamide, 4-[(2R,4aR,10bR)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8,9-dimethoxy-6-phenanthridinyl]-N,N-dipropyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-89-0 CAPLUS

CN Benzenesulfonamide, 4-[(2R,4aR,10bR)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-2-hydroxy-8-methoxy-6-phenanthridinyl]-N,N-dipropyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-90-3 CAPLUS

CN Benzenesulfonamide, 4-[(2R, 4aR, 10bR)-9-ethoxy-1, 2, 3, 4, 4a, 10b-hexahydro-2-hydroxy-8-methoxy-6-phenanthridinyl]-N-(2-methoxyethyl)-N-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-91-4 CAPLUS

CN 2-Phenanthridinol, 8-(difluoromethoxy)-1, 2, 3, 4, 4a, 10b-hexahydro-9-methoxy-6-[4-(1-pyrrolidinylsulfonyl)phenyl]-, (2R, 4aR, 10bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-92-5 CAPLUS

CN 2-Phenanthridinol, 8-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-9-methoxy-6-[4-(1-piperidinylsulfonyl)phenyl]-, (2R,4aR,10bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-93-6 CAPLUS

CN 2-Phenanthridinol, 8-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-9-methoxy-6-[3-(1-pyrrolidinylsulfonyl)phenyl]-, (2R,4aR,10bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-94-7 CAPLUS

CN Benzenesulfonamide, 4-[(2R,4aR,10bR)-8-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-9-methoxy-6-phenanthridinyl]-N,N-dipropyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-95-8 CAPLUS

CN 2-Phenanthridinol, 8-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-9-methoxy-6-[4-(4-morpholinylsulfonyl)phenyl]-, (2R,4aR,10bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-96-9 CAPLUS

CN 2-Phenanthridinol, 8-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-9-methoxy-6-[3-(4-morpholinylsulfonyl)phenyl]-, (2R,4aR,10bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-97-0 CAPLUS

CN 2-Phenanthridinol, 8-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-9-methoxy-6-[3-(1-piperidinylsulfonyl)phenyl]-, (2R,4aR,10bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-98-1 CAPLUS

CN Benzenesulfonamide, 3-[(2R,4aR,10bR)-8-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-9-methoxy-6-phenanthridinyl]-N,N-dimethyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865291-99-2 CAPLUS

CN Benzenesulfonamide, N-cyclopropyl-3-[(2R,4aR,10bR)-8-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-9-methoxy-6-phenanthridinyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865292-00-8 CAPLUS

CN Benzenesulfonamide, 3-[(2R,4aR,10bR)-8-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-2-hydroxy-9-methoxy-6-phenanthridinyl]-N,N-bis(2-methoxyethyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865292-01-9 CAPLUS

CN 2-Phenanthridinol, 8-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-9-methoxy-6-[3-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, (2R,4aR,10bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865292-02-0 CAPLUS

CN 2-Phenanthridinol, 9-(2,2-difluoroethoxy)-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-[3-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, (2R,4aR,10bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865292-03-1 CAPLUS

CN 2-Phenanthridinol, 9-(2,2-difluoroethoxy)-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-[4-(1-pyrrolidinylsulfonyl)phenyl]-, (2R,4aR,10bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865292-04-2 CAPLUS

CN 2-Phenanthridinol, 1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-6-[3-(methylsulfonyl)phenyl]-, (2R,4aR,10bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865292-05-3 CAPLUS

CN 2-Phenanthridinol, 9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-[4-(methylthio)phenyl]-, (2R,4aR,10bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865292-06-4 CAPLUS

CN 2-Phenanthridinol, 9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-[4-(methylthio)phenyl]-, (2R,4aR,10bR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865292-07-5 CAPLUS

CN 2-Phenanthridinol, 9-(2,2-difluoroethoxy)-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-[4-(methylthio)phenyl]-, (2R,4aR,10bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865292-23-5 CAPLUS

CN 2-Phenanthridinol, 9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-[4-(methylsulfinyl)phenyl]-, (2R,4aR,10bR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865292-34-8 CAPLUS

CN 2-Phenanthridinol, 9-(2,2-difluoroethoxy)-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-[3-(methylthio)phenyl]-, (2R,4aR,10bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 865292-35-9 CAPLUS

CN 2-Phenanthridinol, 9-(2,2-difluoroethoxy)-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-[3-(methylsulfinyl)phenyl]-, (2R,4aR,10bR)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 1024706-84-0 1024732-41-9 1024734-74-4
1024736-09-1 1024737-50-5


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of thio-containing phenylphenanthridines as PDE4 inhibitors for treatment of respiratory diseases)

RN 1024706-84-0 CAPLUS

CN 2-Phenanthridinol, 8-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-9-methoxy-6-[4-(1-piperidinylsulfonyl)phenyl]-, 2-acetate, (2R,4aR,10bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 1024732-41-9 CAPLUS

CN 2-Phenanthridinol, 8-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-9-methoxy-6-[4-(4-morpholinylsulfonyl)phenyl]-, 2-acetate, (2R,4aR,10bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 1024734-74-4 CAPLUS

CN 2-Phenanthridinol, 8-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-9-methoxy-6-[3-(1-piperidinylsulfonyl)phenyl]-, 2-acetate, (2R,4aR,10bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 1024736-09-1 CAPLUS

CN 2-Phenanthridinol, 9-(2,2-difluoroethoxy)-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-[3-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, 2-acetate, (2R,4aR,10bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 1024737-50-5 CAPLUS

CN 2-Phenanthridinol, 9-(2,2-difluoroethoxy)-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-[4-(1-pyrrolidinylsulfonyl)phenyl]-, 2-acetate, (2R,4aR,10bR)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 1024780-68-4P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of thio-containing phenylphenanthridines as PDE4 inhibitors for treatment of respiratory diseases)

RN 1024780-68-4 CAPLUS

CN 2-Phenanthridinol, 9-(2,2-difluoroethoxy)-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-[3-(1-pyrrolidinylsulfonyl)phenyl]-, 2-acetate, (2R,4aR,10bR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = OH, alkoxy, cycloalkoxy, etc.; R2 = OH, cycloalkylmethoxy, cycloalkoxy, etc. or R1 and R2 together form alkylenedioxy group; R3 = H or alkyl; R4 = OR9 and R5 = H or alkyl or R4 = H or alkyl and R5 = OR9; R6 = H or alkyl; R7 = (un)substituted guanidinyl; R8 = H, halo, nitro, etc.; R9 = H, alkyl, alkoxyalkyl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as phosphodiesterase 4 (PDE4) inhibitors. Thus, e.g., II was prepared by coupling of 4-((2RS,4aRS,10bRS)-2-acetoxy-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl)-benzoic acid with the resp. guanidinyl derivative followed by hydrolysis. The activity of I was evaluated using scintillation proximity assays and it was revealed that selected compds. of the invention displayed -log IC50 values higher than 7.5. I as inhibitor of PDE4 should provide useful in the treatment of respiratory disorders. Pharmaceutical compns. comprising I are disclosed.

AN 2005:902858 CAPLUS

DN 143:248297

TI Preparation of guanidinyl hydroxyphenylphenanthridines as PDE4 inhibitors
IN Schmidt, Beate; Flockerzi, Dieter; Hatzelmann, Armin; Zitt, Christof; Barsig, Johannes; Marx, Degenhard; Kley, Hans-Peter; Kautz, Ulrich

PA Altana Pharma A.-G., Germany

SO PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005077906	A1	20050825	WO 2005-EP50708	20050217

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,


GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

AU 2005212857 A1 20050825 EP 2004-3592 A 20040218
 AU 2005-212857 20050217
 EP 2004-3592 A 20040218
 WO 2005-EP50708 W 20050217
 CA 2556086 A1 20050825 CA 2005-2556086 20050217
 EP 2004-3592 A 20040218
 WO 2005-EP50708 W 20050217
 EP 1720835 A1 20061115 EP 2005-708038 20050217
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,
 HR, LV, MK, YU

JP 2007523130 T 20070816 EP 2004-3592 A 20040218
 WO 2005-EP50708 W 20050217
 JP 2006-553593 20050217
 EP 2004-3592 A 20040218
 WO 2005-EP50708 W 20050217
 US 20070167482 A1 20070719 US 2006-589082 20060905
 EP 2004-3592 A 20040218
 WO 2005-EP50708 W 20050217

OS CASREACT 143:248297; MARPAT 143:248297
 IT 862993-79-1P 1132891-92-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of guanidinyl hydroxyphenylphenanthridines as PDE4 inhibitors)
 RN 862993-79-1 CAPLUS
 CN Carbamimidothioic acid, [4-[(2R,4aR,10bR)-2-(acetoxy)-1,2,3,4,4a,10b-
 hexahydro-8,9-dimethoxy-6-phenanthridinyl]benzoyl]-, methyl ester, rel-
 (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 1132891-92-9 CAPLUS

CN Carbamimidothioic acid, N-[4-[(2R, 4aR, 10bR)-2-(acetyloxy)-9-(difluoromethoxy)-1,2,3,4,4a,10b-hexahydro-8-methoxy-6-phenanthridinyl]benzoyl]-, methyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT